Final analysis of survival outcomes in the randomized phase 3 FIRST trial.
Facon T et al. Blood. 2017 Nov 17. pii: blood-2017-07-795047. doi: 10.1182/blood-2017-07-795047. [Epub ahead of print].

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D et al. Bone Marrow Transplant. 2017 Oct 30. doi: 10.1038/bmt.2017.208. [Epub ahead of print].

An overview of the role of carfilzomib in the treatment of multiple myeloma.
Ziogas DC et al. Expert Opin Pharmacother. 2017 Nov 14. doi: 10.1080/14656566.2017.1404575. [Epub ahead of print].

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A et al. Br J Haematol. 2017 Nov 21. doi: 10.1111/bjh.14992. [Epub ahead of print].

Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W et al. Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3173-9. [Epub ahead of print].

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA et al. Drugs. 2017 Nov 10. doi: 10.1007/s40265-017-0837-7. [Epub ahead of print].

Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Hoy SM et al. Drugs. 2017 Nov;77(17):1897-1908. doi: 10.1007/s40265-017-0833-y.

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC et al. Pharmacoeconomics. 2017 Oct 31. doi: 10.1007/s40273-017-0581-6. [Epub ahead of print].

The addition of IMiDs on daratumumab refractory multiple myeloma patients can overcome refractoriness in both agents.
Gavriatopoulou M et al. Blood. 2017 Nov 22. pii: blood-2017-10-809293. doi: 10.1182/blood-2017-10-809293. [Epub ahead of print].